| 43.71 -0.55 (-1.24%) | 12-08 13:09 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 53.09 | 1-year : | 62.01 |
| Resists | First : | 45.45 | Second : | 53.09 |
| Pivot price | 42.85  |
|||
| Supports | First : | 37.31 | Second : | 32.27 |
| MAs | MA(5) : | 43.79 |
MA(20) : | 41.52 |
| MA(100) : | 32.09 |
MA(250) : | 0 | |
| MACD | MACD : | 2.1 |
Signal : | 2.1 |
| %K %D | K(14,3) : | 84.4 |
D(3) : | 87.3 |
| RSI | RSI(14): 63.2 |
|||
| 52-week | High : | 45.45 | Low : | 13.36 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ DNTH ] has closed below upper band by 34.0%. Bollinger Bands are 27% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 45.12 - 45.38 | 45.38 - 45.62 |
| Low: | 43.02 - 43.3 | 43.3 - 43.55 |
| Close: | 43.86 - 44.31 | 44.31 - 44.71 |
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Sat, 06 Dec 2025
Dianthus Therapeutics (NASDAQ:DNTH) CFO Ryan Savitz Sells 20,000 Shares - MarketBeat
Fri, 05 Dec 2025
Dianthus Therapeutics (NASDAQ:DNTH) Reaches New 52-Week High - Here's Why - MarketBeat
Fri, 05 Dec 2025
27,003 Shares in Dianthus Therapeutics, Inc. $DNTH Bought by XTX Topco Ltd - MarketBeat
Wed, 03 Dec 2025
Dianthus Therapeutics, Inc. $DNTH Shares Bought by Sio Capital Management LLC - MarketBeat
Wed, 19 Nov 2025
Dianthus Therapeutics (DNTH): Reviewing Valuation Following Widening Losses in Latest Earnings Results - simplywall.st
Sun, 16 Nov 2025
Dianthus Therapeutics Stock (DNTH) Opinions on Recent Price Surge and Clinical Trial Results | DNTH Stock News - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 3.644e+007 (%) |
| Held by Institutions | 5.9 (%) |
| Shares Short | 3,740 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.402e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -10 % |
| Return on Assets (ttm) | 173.7 % |
| Return on Equity (ttm) | -18.9 % |
| Qtrly Rev. Growth | 3.08e+006 % |
| Gross Profit (p.s.) | -61.51 |
| Sales Per Share | -21.49 |
| EBITDA (p.s.) | 2.31579e+006 |
| Qtrly Earnings Growth | -3.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -110 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -2.04 |
| Price to Cash Flow | 4.56 |
| Dividend | 0 |
| Forward Dividend | 4.08e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|